Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…Abstract Number: 1034 • 2019 ACR/ARP Annual Meeting
Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus
Background/Purpose: Recent studies have highlighted the potential role of microRNAs (miRNAs) as diagnostic and prognostic biomarkers in Systemic Lupus Erythematosus (SLE). While Rituximab (RTX) represents…Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting
Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…Abstract Number: 309 • 2019 ACR/ARP Annual Meeting
Increasing Capacity and Reducing Costs of Rituximab Administration
Background/Purpose: Rituximab (RTX) is associated with a large cost burden on the healthcare system and treatment delays that often exceed one month because the long…Abstract Number: 383 • 2019 ACR/ARP Annual Meeting
Retroperitoneal Fibrosis- a Single Center Experience
Background/Purpose: Idiopathic retroperitoneal fibrosis (iRPF) is a rare, chronic, progressive disorder of unknown etiology and characterized by the presence of inflammatory and fibrous retroperitoneal tissue…Abstract Number: 537 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 539 • 2019 ACR/ARP Annual Meeting
A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 793 • 2019 ACR/ARP Annual Meeting
Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare multi-systemic disease characterized by fibrous changes of the skin and internal organs [1]. Patients with “rapidly progressive”…Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…Abstract Number: 1561 • 2018 ACR/ARHP Annual Meeting
B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Background/Purpose: Aim of this study was to assess indications, effectiveness, clinical and ultrasonographic response to rituximab (RTX) therapy in primary Sjögren’s syndrome (pSS), focusing in…
ACR Meeting Abstracts